DPQ

Overview

DPQ is a selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD + /ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6 ) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases.

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PARP

Product Information

• Catalog No.: HY-114869
• CAS No.: 129075-73-6
• Molecular Formula: C18H26N2O2
• Molecular Weight: 302.41
• Purity: 99.68%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source